| Field | Specification |
|---|---|
| Alternative names | TNBG |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C18H16N4 |
| SMILES | |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Tetrazanbigen, also known as TNBG, is a potent, selective antitumor agent that shows strong antitumor efficacy against six human cancer cell lines, with an IC50 range of 2.13-8.01 μg/mL, and an IC50 of 11.25 μg/mL against normal hepatocytes. It induces S phase arrest and apoptosis in QGY-7701 cells, and it exerts its antitumor activity by inducing lipid accumulation in cancer cells[1]. It has the molecular formula C18H16N4 and a molecular weight of 288.35 g/mol.
Physical & Chemical Properties
| CAS Number | 2121990-04-1 |
|---|---|
| Molecular Formula | C18H16N4 |
| Molecular Weight | 288.35 g/mol |
| SMILES | C1(N=C2N3CCC4=C(C=CC=C4)C3CN=C2N5)=C5C=CC=C1 |
| Signaling Pathway | Apoptosis |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with your institution's chemical hygiene plan.
In Vitro
Tetrazanbigen (0-12 μg/mL, 72 h) reduces the proliferation of QGY-7701, BIU-87, Hep-2, SGC-7901, K562, SW626, and LO2 cells, giving IC50 values (in that order) of 2.13, 3.25, 3.84, 4.41, 7.70, 8.01, and 11.25 μg/mL[1].
Lipid accumulation is induced in QGY-7701 cells by Tetrazanbigen (0-8 μg/mL, 24-72 h)[1].
Tetrazanbigen (2-4 μg/mL, 72 h) causes S phase cell cycle arrest and apoptosis in QGY-7701 cells[1].
Cell Cycle Analysis[1]
| Cell Line | QGY-7701 cells |
|---|---|
| Concentration | 2 μg/mL, 4 μg/mL |
| Incubation Time | 72 h |
| Result | Increased the population of S phase, decreased the populations of G0/G1 phases. |
Apoptosis Analysis[1]
| Cell Line | QGY-7701 cells |
|---|---|
| Concentration | 4 μg/mL |
| Incubation Time | 72 h |
| Result | Induced apoptosis, and caused condensed nuclei, apoptotic bodies and cellular shrinkage, chromatin margination. Caused the appearance of a large number of lipid droplets. |
In Vivo
In nude mice, Tetrazanbigen (1.5 mg/kg/day, i.p., 5 weeks) suppresses tumor growth and shows good safety[1].
| Animal Model | Nude mice (Female athymic of 4 weeks old) bearing xenografts of QGY-7701 cell line (5 × 106, s.c.) [1] |
|---|---|
| Dosage | 1.5 mg/kg/day |
| Administration | i.p., 5 weeks |
| Result | Reduced tumor volume and inhibited tumor weight, the TGI based on tumor weight was 87%. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
